Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCL5000
- Development stage
- Preclinical
- Lead developer
- MelliCell
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MCL5000 is an investigational drug candidate being developed by MelliCell for the treatment of obesity and associated metabolic conditions. Currently in the IND-enabling phase, the program is part of MelliCell's adipocyte-centric approach, which focuses on identifying and modulating specific pathways within fat cells to reverse metabolic dysfunction. The company expects to file an Investigational New Drug (IND) application for MCL5000 in 2026. While the specific molecular target has not been disclosed, the therapy aims to address the root causes of obesity by targeting the biology of the adipocyte to restore metabolic health.
Beyond the preview
Go deeper on MCL5000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCL5000.